Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Austin L Hand

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Journal of Biopharmaceutical Statistics|August 12, 2011
BayesWeb: a user-friendly platform for exploratory Bayesian analysis of safety signals from small clinical trialsJohn A Scott, Austin L Hand, Layla S Sian
Computer Methods and Programs in Biomedicine|December 15, 2010
Bayesian sample-size determination for two independent Poisson ratesAustin L Hand, James D Stamey, Dean M Young
Clinical Drug Investigation|January 18, 2022
Effects of Galcanezumab on Health-Related Quality of Life and Disability in Patients with Previous Failure of 2-4 Migraine Preventive Medication Categories: Results from a Phase IIIb Randomized, Placebo-Controlled, Multicenter Clinical Trial (CONQUER)Stewart J Tepper, Jessica Ailani, Janet H Ford, et al.
Clinical Drug Investigation|March 7, 2022
Correction to: Effects of Galcanezumab on Health-Related Quality of Life and Disability in Patients with Previous Failure of 2-4 Migraine Preventive Medication Categories: Results from a Phase IIIb Randomized, Placebo-Controlled, Multicenter Clinical Trial (CONQUER)Stewart J Tepper, Jessica Ailani, Janet H Ford, et al.
Advances in Therapy|September 20, 2021
Galcanezumab in Patients with Multiple Previous Migraine Preventive Medication Category Failures: Results from the Open-Label Period of the CONQUER TrialUwe Reuter, Christian Lucas, David Dolezil, et al.
Headache|February 16, 2023
Changes in migraine interictal burden following treatment with galcanezumab: Results from a phase III randomized, placebo-controlled studyRichard B Lipton, Dawn C Buse, Claire H Sandoe, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|October 7, 2023
Relacorilant, a Selective Glucocorticoid Receptor Modulator in Development for the Treatment of Patients With Cushing Syndrome, Does Not Cause Prolongation of the Cardiac QT IntervalDiane M Donegan, Rosario Pivonello, Antonio Stigliano, et al.
The Lancet. Diabetes & Endocrinology|February 23, 2026
Efficacy and safety of relacorilant for the treatment of patients with Cushing's syndrome (GRACE): a multicentre, phase 3, double-blind, placebo-controlled, randomised-withdrawal studyRosario Pivonello, Giorgio Arnaldi, Richard J Auchus, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Journal of Biopharmaceutical Statistics|August 12, 2011
BayesWeb: a user-friendly platform for exploratory Bayesian analysis of safety signals from small clinical trialsJohn A Scott, Austin L Hand, Layla S Sian
Computer Methods and Programs in Biomedicine|December 15, 2010
Bayesian sample-size determination for two independent Poisson ratesAustin L Hand, James D Stamey, Dean M Young
Clinical Drug Investigation|January 18, 2022
Effects of Galcanezumab on Health-Related Quality of Life and Disability in Patients with Previous Failure of 2-4 Migraine Preventive Medication Categories: Results from a Phase IIIb Randomized, Placebo-Controlled, Multicenter Clinical Trial (CONQUER)Stewart J Tepper, Jessica Ailani, Janet H Ford, et al.
Clinical Drug Investigation|March 7, 2022
Correction to: Effects of Galcanezumab on Health-Related Quality of Life and Disability in Patients with Previous Failure of 2-4 Migraine Preventive Medication Categories: Results from a Phase IIIb Randomized, Placebo-Controlled, Multicenter Clinical Trial (CONQUER)Stewart J Tepper, Jessica Ailani, Janet H Ford, et al.
Advances in Therapy|September 20, 2021
Galcanezumab in Patients with Multiple Previous Migraine Preventive Medication Category Failures: Results from the Open-Label Period of the CONQUER TrialUwe Reuter, Christian Lucas, David Dolezil, et al.
Headache|February 16, 2023
Changes in migraine interictal burden following treatment with galcanezumab: Results from a phase III randomized, placebo-controlled studyRichard B Lipton, Dawn C Buse, Claire H Sandoe, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|October 7, 2023
Relacorilant, a Selective Glucocorticoid Receptor Modulator in Development for the Treatment of Patients With Cushing Syndrome, Does Not Cause Prolongation of the Cardiac QT IntervalDiane M Donegan, Rosario Pivonello, Antonio Stigliano, et al.
The Lancet. Diabetes & Endocrinology|February 23, 2026
Efficacy and safety of relacorilant for the treatment of patients with Cushing's syndrome (GRACE): a multicentre, phase 3, double-blind, placebo-controlled, randomised-withdrawal studyRosario Pivonello, Giorgio Arnaldi, Richard J Auchus, et al.
Pageof 1